Suven Life Sciences receives product patents in Europe, South Korea
Suven Life Sciences Limited (Suven) informed the bourses on Tuesday that it has secured product patents in Europe and South Korea. These patents will be valid through 2033 and 2034.
These granted patents are corresponding to the New chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases including Alzheimer’s, attention deficient hyperactivity disorder (ADHD), schizophrenia, Huntington’s disease and Parkinson’s.
Last month, the company received the grant of the product patents in New Zealand and Norway.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.
On Monday, the stock opened at Rs. 217 per share and touched an intraday high and low of Rs. 218 and Rs. 214.40, respectively, on the BSE.